Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Out Of The Ashes: Roche’s Dalcetrapib Data Suggest Still Hope For CETP Inhibitor Class

Nov 12 2012

• By Sue Sutter

Related Content

Merck’s Anacetrapib Debut Many Years Away, Despite Robust Phase III Data

Nov 22 2010

Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol

May 14 2012

Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet

Dec 11 2006

Roche Exorcizes Torcetrapib’s Ghost: CETP Candidate Starts Phase III

May 01 2008

Merck Taking Aggressive Approach To Cardiovascular Development

Jan 05 2009

Merck, Lilly Vow To Press On With CETP, Despite Dalcetrapib Disaster

May 07 2012

Related Companies

Merck & Co., Inc.

Eli Lilly and Company

Roche Holding AG

Pfizer Inc.

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window